News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

All
News
Press Releases
News

From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need

December 6, 2024

Forbes Healthcare Summit

Read Now
News

Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies

November 27, 2024

Inside Precision Medicine

Read Now
News

The 2024 PharmaVoice 100

October 8, 2024

PharmaVoice

Read Now
News

Engineering The Future Of Genetic Medicine

September 10, 2024

Progress, Potential, and Possibilities

Read Now
News

Leadership essentials: “Inspire, motivate, and cultivate”

September 9, 2024

BigThink

Read Now
News

Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

August 5, 2024

BioSpace

Read Now
Press release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now
Press release

Scribe Therapeutics Co-Founder Jennifer Doudna Receives 2020 Nobel Prize in Chemistry

October 9, 2020

Read Now
Press release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now
Press release

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

October 6, 2020

Read Now

Publications